Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD

8.69  -1.16 (-11.78%)

After market: 9.14 +0.45 (+5.18%)

Fundamental Rating

3

Overall ACOG gets a fundamental rating of 3 out of 10. We evaluated ACOG against 561 industry peers in the Biotechnology industry. While ACOG has a great health rating, there are worries on its profitability. ACOG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACOG had negative earnings in the past year.
ACOG had a negative operating cash flow in the past year.
ACOG had negative earnings in each of the past 5 years.
In the past 5 years ACOG always reported negative operating cash flow.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ACOG has a Return On Assets of -28.85%. This is in the better half of the industry: ACOG outperforms 66.67% of its industry peers.
With a decent Return On Equity value of -35.30%, ACOG is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
ROA -28.85%
ROE -35.3%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

ACOG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ACOG has been increased compared to 1 year ago.
The debt/assets ratio for ACOG has been reduced compared to a year ago.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

ACOG has an Altman-Z score of 7.24. This indicates that ACOG is financially healthy and has little risk of bankruptcy at the moment.
ACOG has a Altman-Z score of 7.24. This is amongst the best in the industry. ACOG outperforms 83.24% of its industry peers.
ACOG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.24
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 15.00 indicates that ACOG has no problem at all paying its short term obligations.
The Current ratio of ACOG (15.00) is better than 89.48% of its industry peers.
ACOG has a Quick Ratio of 14.81. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.
ACOG's Quick ratio of 14.81 is amongst the best of the industry. ACOG outperforms 88.41% of its industry peers.
Industry RankSector Rank
Current Ratio 15
Quick Ratio 14.81
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

ACOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.09%.
EPS 1Y (TTM)-40.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACOG will show a very negative growth in Earnings Per Share. The EPS will decrease by -397.49% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3562.5%
EPS Next 2Y-397.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 10M 20M 30M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACOG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACOG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as ACOG's earnings are expected to decrease with -397.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-397.49%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACOG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA COGNITION INC

NASDAQ:ACOG (5/22/2025, 8:00:00 PM)

After market: 9.14 +0.45 (+5.18%)

8.69

-1.16 (-11.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)N/A N/A
Inst Owners39.47%
Inst Owner ChangeN/A
Ins Owners6.55%
Ins Owner Change0%
Market Cap139.21M
Analysts82.86
Price Target20.4 (134.75%)
Short Float %0.25%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.43%
Min EPS beat(2)-4.17%
Max EPS beat(2)99.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.36
P/tB 3.39
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS2.59
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.85%
ROE -35.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15
Quick Ratio 14.81
Altman-Z 7.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.46%
EPS Next Y-3562.5%
EPS Next 2Y-397.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.86%
OCF growth 3YN/A
OCF growth 5YN/A